PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8
Clinical trials for PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted combo tested for tough breast cancer
Disease control TerminatedThis study tested whether adding a targeted drug called alpelisib to a chemotherapy drug (nab-paclitaxel) could help shrink tumors before surgery. It was for people with a specific, hard-to-treat type of breast cancer (triple-negative) that had not responded well to a common firs…
Matched conditions: PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug tested to fight back against stubborn breast cancer
Disease control TerminatedThis study tested if a drug called abemaciclib could help control a hard-to-treat type of breast cancer that did not fully respond to standard chemotherapy. It involved 26 women whose cancer could still be surgically removed. The goal was to see if taking the drug for a short per…
Matched conditions: PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
Trial aims to tame harsh chemo gut side effects
Symptom relief TerminatedThis study tested whether the antibiotic rifaximin could reduce severe stomach pain, diarrhea, and other gut problems caused by a standard breast cancer drug combination. It involved 20 women with early-stage HER2-positive breast cancer who were experiencing these side effects. T…
Matched conditions: PROGNOSTIC STAGE IIB BREAST CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC